Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:

NCT ID: NCT03443115 Recruiting - Clinical trials for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Heart Study

DMD-HS
Start date: June 27, 2017
Phase: N/A
Study type: Observational

Retrospective cohort study including patients with genetically proven Duchenne muscular dystrophy, diagnosed from January 1993 to March 2020. Inclusion of the data relative to genetic diagnosis, clinical characteristics at baseline, cardiac and respiratory workup, medical treatments (ACE inhibitors, steroids), surgical procedures, and occurrence during follow-up of cardiac, respiratory and fatal events. Objectives are to describe long-term natural history of the disease, vital prognosis, genotype-phenotype correlations, effect of treatments.

NCT ID: NCT03437642 Recruiting - Breast Cancer Clinical Trials

Psyhosomatic Medicine in Oncologic and Cardiac Disease Study

PSYCHONIC
Start date: March 27, 2018
Phase:
Study type: Observational [Patient Registry]

Psychological processes play a complex role in the pathophysiology of many diseases. However, the body and emotional perception of patients and the relationship between dreams and disease still need to be investigated. The investigators planned an observational and controlled research aimed at assessing some previously unaddressed baseline psychological characteristics and their changes at 1 and 5 years after a short-term psychotherapy in carefully characterised patients with heart or oncologic diseases . The patients that will be enrolled are: - 50 patients ≤ 75 year old with acute myocardial infarction; - 30 patients ≤ 75 year old with Tako-Tsubo syndrome; - 50 women ≤ 75 year old, recently operated on breast cancer: - 90 control subjects of the same age and gender of the enrolled patients, without relevant pathologies during the last 10 years. Relevant pathologies are defined as those that required a hospitalisation or a long-lasting medical therapy. At the enrolment all the subjects will undergo a complete medical evaluation, and the following psychometric tests: Self-evaluation test, Social Support Questionnaire, Beck Depression Inventory II (BDI II), MacNew Heart Disease Health-Related Quality of Life Questionnaire, State-Trait Anxiety Inventory (STAI), State-Trait Anger Expression Inventory (STAXI 2). In two distinct following meetings, an open questionnaire exploring the body and emotional perception, and another exploring past and recent dreams, will be administered. The same evaluation will be done for the healthy subjects. After the initial evaluation, all the patients will be given the choice to start a short-term psychotherapy lasting 6 months on top of medical therapy or to continue classic medical therapy only. Healthy subjects will be not offered the possibility to follow psychotherapy. At first year of follow-up, the battery of psychometric test, and the two questionnaires exploring the body and emotional perception, and changes and characteristics of dreams during the psychotherapy, will be re-administered. The following data will be evaluated: Psychological characteristics at follow-up. Incidence of new relevant medical events Quality of life Relationship between psychological characteristics and health status, and quality of life At 5 year follow-up psychometric tests and the clinical data will be evaluated in all the groups.

NCT ID: NCT03397810 Recruiting - Clinical trials for Amyloid Cardiomyopathy

Effect of Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study

Start date: March 15, 2019
Phase: N/A
Study type: Interventional

Cardiac amyloidosis is responsible for significant morbidity associated with heart failure, and carries a poor prognosis. Currently there are very limited treatment options for this condition. Radiotherapy has been used successfully to treat amyloidosis elsewhere in the body, however has not been tried in cardiac amyloidosis. Therefore this study aims to assess the effect of radiotherapy on cardiac amyloidosis, to evaluate whether it can successfully reduce the burden of amyloid deposits in the myocardium as assessed by 18F-Amyloid PET.

NCT ID: NCT03372577 Recruiting - Sexual Dysfunction Clinical Trials

Mindfulness-based Sex Therapy on Patients With Takotsubo Cardiomyopathy

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Takotsubo cardiomyopathy (TC) is a type of non-ischemic cardiomyopathy in which there is a sudden temporary weakening of the myocardium. . In a recent study, women report more sexual dysfunction than men after 1 year after TC. Despite that a number of studies have assessed female sexual dysfunction (FSD) for TC , there is no information regarding prevalence and associated factors on FSD in women with TC. However, in a recent study on Iranian female patients with TC, more than 77% of these patients suffered from FSD. This study is aimed to assess the effectiveness of a Mindfulness-based Sex Therapy on Patients With TC.

NCT ID: NCT03364140 Recruiting - Clinical trials for Peripartum Cardiomyopathy

A Registry of Peripartum Cardiomyopathy in Turkey

Start date: July 2, 2017
Phase: N/A
Study type: Observational

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality of young women. Its' etiology, epidemiology and treatment is not yet well described. This will be a retrospective, national, multicenter observational study, conducted in Turkey. It is expected that approximately 50 women with PPCM will be recorded.

NCT ID: NCT03362164 Recruiting - Fabry Disease Clinical Trials

Evaluation of HEArt invoLvement in Patients With FABRY Disease

HEAL-FABRY
Start date: January 2001
Phase:
Study type: Observational

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

NCT ID: NCT03340675 Recruiting - Clinical trials for Cardiomyopathy, Dilated

Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

DMD
Start date: October 19, 2020
Phase: Phase 2
Study type: Interventional

Duchenne muscular dystrophy (DMD) is a devastating X-linked disease which leads to loss of ambulation between ages 7 and 13, respiratory failure and cardiomyopathy (CM) at any age, and inevitably premature death of affected young men in their late twenties. DMD is the most common fatal genetic disorder diagnosed in childhood. It affects approximately 1 in every 3,500 live male births across all races and cultures, and results in 20,000 new cases each year worldwide.Significant advances in respiratory care have unmasked CM as the leading cause of death. As there are yet no specific cardiac treatments to extend life, the current study aims to address this unmet medical need using a new therapeutic strategy for patients with DMD. Funding Source - FDA OOPD

NCT ID: NCT03327623 Recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)

Start date: November 13, 2017
Phase:
Study type: Observational

The investigators are trying to find out how common sleep apnea is in hypertrophic cardiomyopathy. The purpose of this study is to see if sleep apnea is common in hypertrophic cardiomyopathy and if its presence is associated with changes in the functioning of the body. The investigators want to determine if sleep apnea is associated with electrical disorders of the heart in patients with hypertrophic cardiomyopathy.

NCT ID: NCT03317964 Recruiting - Cardiomyopathies Clinical Trials

Genetic Basis of Pacing-induced Cardiomyopathy

Start date: October 16, 2017
Phase:
Study type: Observational

The purpose of this study is to collect a saliva sample from patients with a pacemaker to study genes involved in cardiomyopathy, a condition where the heart muscle is abnormal.

NCT ID: NCT03304847 Recruiting - Cardiomyopathy Clinical Trials

Arrhythmogenic Substrate in Primary Cardiomyopathies and/or Channellopathies

Start date: January 24, 2018
Phase: N/A
Study type: Interventional

This study assesses the value of arrhythmogenic substrate identification and elimination by catheter ablation to prevent recurrent ventricular arrhythmias and sudden cardiac death in a series of selected patients with primary cardiomyopathy and/or channellopaties with ICD implantation.